Source link : https://www.newshealth.biz/health-news/first-drug-okd-for-chronic-rhinosinusitis-with-nasal-polyps-in-adolescents/
The FDA broadened dupilumab’s (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps to include adolescents as well, Regeneron Pharmaceuticals announced. With the expended indication, the interleukin (IL-4) receptor alpha antagonist is approved for use in children ages 12 to 17 years with inadequately controlled disease, making it the only approved […]
Author : News Health
Publish date : 2024-09-17 18:45:16
Copyright for syndicated content belongs to the linked Source.